ESTRO 2024 - Abstract Book

S120 ESTRO 2024 Modern oncology increasingly enables oncologists to specifically target tumor cells using the immune system to fight the disease. In recent years, we have learnt about the different factors that predict the (potential) success of immunotherapyas molecular pathology, tumor microenvironment, microbiome or tumor mutational burden and serum markers of immunogenicity. Meanwhile, we see long-term survivors in cancers such as malignant melanoma or non-small cell lung cancer, which was unthinkable ten years ago. In colorectal cancer, immunotherapy has revolutionized treatment algorithms, and in the palliative setting, immunotherapy can turn fatal metastatic cancers into chronic diseases with patients surviving for years. Individualized treatment including individualized specific targeted agents, various immunotherapeutic approaches and local treatments is the future of systemic treatment. Invited Speaker

3533

The physcisist's perspective

Daniela Thorwarth

Section for Biomedical Physics, Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany

Abstract:

In this presentation, the rationale and motivation for hypofractionation from a medical physics point of view will be reviewed in terms of classical cell survival and tumor control probability models. Effects of varying different variables, such as total number of fractions, fraction dose or total dose will be revisited.

Further, implications and requirements for the clinical application of hypofractionation in terms of stereotactic body radiotherapy (SBRT) or brachytherapy treatment planning, delivery and quality assurance will be discussed.

3535

The role of brachytherapy (interventional radiotherapy) dose escalation for organ preservation in head & neck cancer

Ashwini Budrukkar

Tata Memorial Hospital, Department of Radiation Oncology, Homi Bhabha National Institute, Mumbai, India

Abstract:

Brachytherapy (Interventional Radiotherapy) is an integral component of treatment of Head neck cancers with radiation. It can be considered as radical BT alone, boost to external beam radiation therapy (EBRT), as an adjuvant BT and in treatment of recurrences. Boost BT is considered useful for escalation of dose which may be required in patients with high risk of recurrence. It also helps in reducing doses to the critical structures thereby preserving normal organs at risk and function. Boost BT is considered in situations where irradiation of neck is necessary for taking care of the nodal metastasis. Subsites where boost BT is considered are tongue cancers, oropharyngeal cancers, nasopharynx and paranasal sinus tumours.